Unveiling New Triazoloquinoxaline‐Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9
Chemistry – A European Journal · 2025
DOI: 10.1002/chem.202404218 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2025. Verfasst von Martina Pierri und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, Fisciano, 84084, Italy. Hauptthemen laut MEDLINE: Quinoxalines, Transcription Factors, Triazoles. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
PROteolysis Targeting Chimera (PROTAC) technology is an innovative and potent approach for achieving targeted protein degradation (TPD). Within bromodomain‐containing proteins, various degraders targeting BET family‐related targets, for example, BRD4, were developed in the last years. On the other hand, a limited number of PROTACs acting against non‐BET proteins were reported so far. Among them, BRD9 was recently linked to oncogenic roles in the tumorigenesis processes, especially in sarcomas and leukemias. Herein, we describe the design and synthesis of a focused collection of new BRD9‐targeting degraders based on the [1,2,4]triazolo[4,3‐ a ]quinoxaline heterocyclic scaffold employing two distinct E3 ubiquitin ligase ligands. Through in silico evaluation, synthesis, binding affinity determination, and in vitro analysis, we identified two new VHL‐based PROTACs ( 2 and 9 ), which showed remarkable degradation of the protein of interest and antiproliferative activity in acute myeloid leukemia (AML) cells. Notably, compound 9 exhibited selective degradation of BRD9 over BRD7. These results enlarge and differentiate the pool of heterobifunctional molecules able to degrade BRD9 through the proteasome machinery, providing a promising reference for the discovery of new tools to further explore both the involvement of this epigenetic regulatory factor in tumor processes and to evaluate novel strategies for AML treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, Fisciano, 84084, Italy.
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Vico L. De Crecchio 7, Naples, 80138, Italy.
- PhD Program in Drug Discovery and Development, University of Salerno, Via Giovanni Paolo II 132, Fisciano, 84084, Italy.
- Department of Biosciences and Territory, University of Molise, C.da Fonte Lappone, Pesche, 86090, Italy.
- Program of Medical Epigenetics, Vanvitelli Hospital, Naples, Italy.
- BIOGEM, Via Camporeale Area P.I.P., Ariano Irpino (AV), Italy.
ORCID-Profile: Giuseppe Bifulco
Zitieren
APA
Pierri, M., Bove, G., Gazzillo, E., Colarusso, E., Scala, F., Pepe, G., Terracciano, S., Chini, M. G., Simonelli, N., Bruno, I., Nebbioso, A., Campiglia, P., Bifulco, G., Altucci, L., Del Gaudio, N., & Lauro, G. (2025). Unveiling New Triazoloquinoxaline‐Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9. Chemistry – A European Journal. https://doi.org/10.1002/chem.202404218
Vancouver
Pierri M, Bove G, Gazzillo E, Colarusso E, Scala F, Pepe G, et al. Unveiling New Triazoloquinoxaline‐Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9. Chemistry – A European Journal. 2025. doi:10.1002/chem.202404218
BibTeX
@article{Pierri2025,
author = {Pierri, Martina and Bove, Guglielmo and Gazzillo, Erica and Colarusso, Ester and Scala, Francesca and Pepe, Giacomo and Terracciano, Stefania and Chini, Maria Giovanna and Simonelli, Nicla and Bruno, Ines and Nebbioso, Angela and Campiglia, Pietro and Bifulco, Giuseppe and Altucci, Lucia and Del Gaudio, Nunzio and Lauro, Gianluigi},
title = {Unveiling New Triazoloquinoxaline‐Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9},
journal = {Chemistry – A European Journal},
year = {2025},
doi = {10.1002/chem.202404218}
}
EUVIMED